Fareston Toremifene_Citrate_Is__Selective_Estrogen_Receptor_Modulator_

← Homepage



Fareston, the registered trademark of GTx, Inc. in the United States, is popularly under its chemical name as Tremifene Citrate. It is a SERM (Selective Estrogen Receptor Modulator) that helps to inhibit the actions of estrogen in the body. The drug is popularly termed as Fareston-Toremifene Citrate.

Fareston-Toremifene Citrate is medically used to treat breast cancer. It helps to treat breast cancer by secreting estrogen antagonistic effects in breast tissue. It is sometimes also used for prevention of prostate cancer. The FDA has approved the drug for use in treating advanced (metastatic) breast cancer in the United States. Fareston-Toremifene Citrate is also effective in preventing abnormal growth of breast tissue in men.

Fareston-Toremifene Citrate comes in tablets that are taken orally. The active ingredients of the drug include colloidal silicon dioxide, starch, povidone, lactose, magnesium stearate, sodium starch glycolate, and microcrystalline cellulose. The chemical formula of Fareston-Toremifene Citrate is C26H28ClNO. The drug acts as an estrogen antagonist in the hypothalamus and pituitary in order to increase testosterone levels in body.

Often, Fareston-Toremifene Citrate is compared with Nolvadex, but it differs from that drug in several ways. First, Fareston-Toremifene Citrate has fewer side effects as compared to Nolvadex, and secondly, its lowers down the risks of various deadly diseases, such as cataract, Stroke, and pulmonary embolism. As compared to Nolvadex, Fareston-Toremifene Citrate has greater ability to increase the LH levels. In a steroid cycle, Fareston-Toremifene Citrate helps to prevent gynecomastia. That is why, many bodybuilders feel that Fareston-Toremifene Citrate is better than Nolvadex.

Fareston-Toremifene Citrate, however, has its own side effects. According to a North American Study, Fareston-Toremifene Citrate is responsible for causing Hot Flashes in 35% of users, Sweating in 20% of users, Nausea in 14% of users, Vaginal Discharge in 13% of users, Dizziness in 9% of users, Edema in 5% of users, Vomiting in 4% of users, and Vaginal Bleeding in 2% of users. Some of the other side effects associated with the use of Fareston-Toremifene Citrate include � cardiac failure, arrhythmia, corneal keratopathy, glaucoma, thrombosis, pulmonary embolism, leukopenia, asthenia, alopecia, jaundice, and depression.

These side effects are the major reason that Fareston-Toremifene Citrate is not approved by FDA, which has sent warning letters to its manufacturer, and ordered the company to stop the production of the drug immediately. GTx, Inc. is presently conducting clinical trials on the drug.